AG7088

AG7088

A rhinovirus 3C protease inhibitor (anti-viral) intended for use on the common cold. It made it as far as Phase II trials before Agouron stopped development.
References in periodicals archive ?
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
They believe the virus could be treated by a modified version of an experimental common cold drug called AG7088.
today reported significant improvements in cold symptoms among volunteers given intranasal doses of its investigational compound AG7088 targeting human rhinovirus (the most frequent cause of the common cold) following experimentally induced rhinovirus infection.
Agouron's rhinovirus 3C protease inhibitor AG7088 is in human clinical trials for the proposed treatment of the common cold.
The American drug company Agouron Pharmaceuticals have come closest with a drug called AG7088 that stops the cold virus reproducing.
Currently in Phase II studies, AG7088 could enter large scale Phase III clinical studies later this year and possibly lead to an NDA by the end of 2001.
pro] inhibitors may be useful for SARS therapy, but results of recent in vitro testing of the lead molecule, AG7088, were negative (3).
tested its investigational drug which at this time only has the technical name of AG7088 on more than 200 people sequestered for several days in hotel rooms across the country.
today announced that it has initiated a large double blind, placebo controlled clinical trial to evaluate its investigational compound AG7088 (intranasal spray) for the treatment of common colds caused by the rhinovirus infection.
Nasdaq: AGPH) today announced that it has initiated human clinical trials of its compound AG7088 targeting human rhinovirus, the most frequent cause of the common cold.
The test is being developed with the immediate goal of having a diagnostic available to assist in the clinical development phase of Agouron's rhinovirus therapeutic product candidate, AG7088.
Nasdaq: AGPH) reported favorable results from preclinical studies of its compound AG7088 targeting human rhinovirus, the most frequent cause of the common cold.